A stained glass-style illustration of a hand holding a torch with a flame, with the hand depicted in shades of blue and the torch in shades of brown and orange.

A Prescription For Fairness : Fixing Drug Pricing And Access Plan

Too many families are burdened by the rising cost of medications they depend on. Our system rewards profit over public health, even when taxpayer dollars fund the science.

It's time to create a fair and transparent process that puts patients, not corporations, at the center of care. We can build a future where innovation and access go hand in hand—without compromising the health of Americans.

Essential Medicines Cap Act

Place a 15% Profit Margin Cap PER DOSE for life-saving or essential medications.

- Ensure affordability for patients who depend on these drugs
- Ensure companies disclose manufacturing / R & D Costs
- Shift costs down after R & D is recovered

EXAMPLES include medicines or treatments for :
Diabetes, Allergies, Asthma & Respiratory, HIV/AIDS, Infectious diseases, Mental Stability, Cancer Treatments

Global Price Fairness Act

Non-Essential, Brand-Name Drugs are capped at 1.5 - 2x Organization for Economic Cooperation and Development Countries.

- U.S. Drug prices are currently 2.8x than OECD Markets
- U.S. Brand Name Drug Prices are up to 4.22x OECD Markets

Raising foreign prices to reduce the rate change effect would be seen as market manipulation.

Public Research & Public Benefit Act

Public funds help develop essential drugs and these funds need to be tied to fairer drug prices.
”When we fund the cure, we deserve the care”

- Guarantee affordable access for the public to medicines and treatments that are developed with public tax dollars.
- Set pricing reductions as a percentage of the total public investment compared to total R & D Costs

When we align federal investment and innovation with public benefits, we all win

Medical Marketing Allocation Act

Disincentivize Medical Marketing by imposing an increased marketing tax and promoting a national medical journal
”Ensuring patients and doctors have full access to all treatments”

- Drugmakers and Treatment options that forgo advertising are included in a journal available at all Medical Offices, Courthouses, Digital, and Dial-In Services showcasing :
- Emerging Treatments
- Experimental Treatments
- Newly Approved Treatments
- Generic Treatments
- Pharmaceutical or Treatment companies pay a 15% Tax on money spent marketing to doctors or consumers.